Clinical trial · Interventional

Investigation of Clofarabine in Acute Leukemias

Phase II Clinical and Pharmacodynamic Investigation of Clofarabine in Acute Leukemias

NCT00098033CI-TRIAL-00017231completedPhase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The goals and objectives of this project are to evaluate the antileukemic activity of the investigational agent clofarabine in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) in accelerated and blastic phases.

Conditions

Conditions (3)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Acute Lymphocytic Leukemia	Acute Lymphoblastic Leukemia	ALIAS	0.90
Acute Myelogenous Leukemia	Acute Myeloid Leukemia	ALIAS	0.90
Chronic Myelogenous Leukemia	Myeloid Leukemia	CURATED_BROADER	0.80

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
clofarabine	Drug	Clofarabine	ALIAS

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 12 Years

Show eligibility criteria text

* Patient is diagnosed with AML, ALL, myelodysplastic syndrome (MDS), and CML in transformation (includes CML-blastic phase and CML-accelerated phase).
* No prior chemo-, immuno-, or radio-therapy for 2 weeks before entering the study, unless progressive life-threatening leukemia as judged by the treated physician.
* Adequate liver function (bilirubin \</= 2 mg%) and renal function (creatinine \</= 2 mg%).
* Pregnant and lactating females not eligible.
* Zubrod performance status 0-2
* Adequate cardiac status
* No life-threatening conditions (e.g. infections) which may cause death within 3 weeks.

References

Publications (1)

BACKGROUNDCortes JE, Gandhi V, et al. Clofarabine (2-chloro-9-(deoxy-2-fluoro-b-D-arabinosfuranosyl)adenine) is active for patients with refractory or relapsed acute leukemia. #739 ASH 2002.